By SPC Staff
The FDA approved an autoinjector option for adalimumab-adbm (Cyltezo, Boehringer Ingelheim), an interchangeable biosimilar of adalimumab (Humira, AbbVie).
Adalimumab-adbm was initially approved as a prefilled syringe to treat chronic inflammatory diseases such as Crohn’s disease, ulcerative colitis, plaque psoriasis and rheumatoid arthritis. The 40 mg/0.8 mL Cyltezo Pen will be available on July 1, 2023. It features a one-button, three-step activation with “100%